Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting
Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…Abstract Number: 337 • 2019 ACR/ARP Annual Meeting
Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study
Background/Purpose: Gout is a disorder of uric acid metabolism and often presents as acute severe joint pain. Previous work from our group suggests that all-cause…Abstract Number: 1405 • 2019 ACR/ARP Annual Meeting
Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab
Background/Purpose: Adipose tissue is an important player in cardiovascular (CV) morbidity. Thermogenic brown adipocytes, rich with uncoupling protein 1 (UCP1), increase metabolic and CV health.…Abstract Number: 2410 • 2019 ACR/ARP Annual Meeting
Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable
Background/Purpose: BMI is a well-known confounding factor in the association between osteoarthritis (OA) and cardiovascular diseases (CVD). However, BMI is not usually recorded in administrative…Abstract Number: 345 • 2019 ACR/ARP Annual Meeting
Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey
Background/Purpose: The cardiovascular risk of gout is already well known, and the debate over the cardiovascular risk of uric acid lower agents is currently hot.…Abstract Number: 1626 • 2019 ACR/ARP Annual Meeting
Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Background/Purpose: Background/purpose Premature atherosclerosis has been recognized as a major cause of morbidity and mortality in SLE patients. We aimed to determine 1) the incidence…Abstract Number: 2456 • 2019 ACR/ARP Annual Meeting
Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Background/Purpose: Valuable information on cardiovascular disease outcomes can be obtained from large cohort studies. Such studies often rely on self-reported events, which are best validated…Abstract Number: 346 • 2019 ACR/ARP Annual Meeting
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…Abstract Number: 1851 • 2019 ACR/ARP Annual Meeting
The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
Background/Purpose: African Americans (AA) are more likely to experience psychosocial and environmental stressors and develop SLE than whites. Increasing frequency of racial discrimination is associated…Abstract Number: 2515 • 2019 ACR/ARP Annual Meeting
Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis
Background/Purpose: Objectives. The addition of carotid ultrasound CU into composite cardiovascular risk (CVR) scores has been found useful in the identification of high CVR in…Abstract Number: 373 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis
Background/Purpose: To identify prognostic factors and to assess the effects of immunosuppressive drugs on relapse risk in patients presenting with cardiac sarcoidosis (CS).Methods: From a…Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…Abstract Number: 2013 • 2019 ACR/ARP Annual Meeting
Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD). Prior reports have suggested that “dysfunctional” HDL may explain…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 38
- Next Page »